Ascletis initiates US Phase I trial of once-monthly obesity drug candidate ASC36_35FDC

• Ascletis initiated two Phase I U.S. trials for obesity, testing ASC36 and a once-monthly fixed-dose combination, ASC36_35FDC.
• The studies will assess safety and drug behavior in people with obesity or overweight with related conditions, using single or multiple dose escalation.
• No clinical results have been presented yet; prior efficacy signals cited were from animal studies comparing the candidates with rival regimens.
• The program positions Ascletis for a less frequent injection approach, aiming to compete in a crowded obesity market dominated by weekly therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12278901), on August 10, 2026, and is solely responsible for the information contained therein.